Industry News
15 Oct
Next-Generation Biomanufacturing: The Future of Cell & Gene Therapy Scale-Up
Introduction Cell and gene therapies (CGTs) are reshaping the treatment landscape for complex diseases, including certain cancers, rare genetic disorders, and inherited conditions. These therapies offer the potential to address disease at the cellular or genetic level, creating new opportunities for personalized and potentially transformative treatment. However, scientific progress alone does not guarantee commercial […]
14 Oct
Next-Generation Biomanufacturing Becomes a Strategic Differentiator
Next-Generation Biomanufacturing Becomes a Strategic Differentiator Introduction: Manufacturing Is Becoming a Competitive Advantage Biopharmaceutical innovation is advancing rapidly, driven by progress in monoclonal antibodies, cell and gene therapies, recombinant proteins, RNA-based medicines, and other advanced therapeutic modalities. However, scientific breakthroughs alone do not guarantee commercial success. The ability to manufacture complex biological products consistently, at […]
13 Oct
Computer-Aided Diagnosis Moves Toward Broader Clinical Adoption
Computer-Aided Diagnosis Moves Toward Broader Clinical Adoption Introduction: From Diagnostic Assistance to Clinical Decision Support Medical diagnostics is undergoing a significant transformation as healthcare providers increasingly explore technologies that can improve diagnostic accuracy, support clinical decision-making, and manage growing workloads. Computer-aided diagnosis (CAD) is becoming an important part of this transition, evolving from specialized image-analysis […]
12 Oct
In-Vivo Gene Editing Emerges as a New Direction for Cell & Gene Therapy
In-Vivo Gene Editing Emerges as a New Direction for Cell & Gene Therapy Introduction: A Shift in the Gene Therapy Paradigm Gene editing is entering a new phase in which researchers are increasingly exploring ways to modify genetic material directly inside a patient’s body. Known as in-vivo gene editing, this approach could change how certain […]
09 Oct
GLP-1 Success Is Reshaping Pharma Investment Priorities
GLP-1 Success Is Reshaping Pharma Investment Priorities Introduction: From Therapeutic Breakthrough to Strategic Investment Priority The rapid growth of glucagon-like peptide-1 (GLP-1) receptor agonists has become one of the most consequential developments in the pharmaceutical industry. Initially established as treatments for type 2 diabetes, medicines targeting the GLP-1 pathway have gained significant commercial attention for […]
08 Oct
CAR-T Moves Beyond Oncology
CAR-T Moves Beyond Oncology: Could Immune Reset Become the Next Frontier? By Eminent Global Research Solutions Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape for several blood cancers. But the next chapter of CAR-T may not be defined by oncology alone. Researchers are increasingly investigating whether the same cellular-engineering principles used […]
07 Oct
AI Drug Discovery Faces the Challenge of Translating Data Into Clinical Success
Artificial intelligence is rapidly changing how pharmaceutical companies identify targets, design molecules, predict properties, and prioritize drug candidates. From protein-structure prediction and virtual screening to de novo molecular design and multimodal analysis, AI can compress parts of the discovery process that traditionally required years of experimentation. But a critical question is becoming increasingly important: Can […]
05 Oct
Pharma M&A Accelerates as Patent Cliff Pressure Builds
How loss-of-exclusivity exposure is reshaping pharmaceutical portfolio strategy, dealmaking, and competitive positioning The pharmaceutical M&A landscape is entering a strategically important phase. Large drugmakers are facing increasing pressure to replace revenue that could be eroded as blockbuster medicines approach loss of exclusivity (LOE), while at the same time seeking exposure to new growth markets, differentiated […]
01 Oct
FDA Advances Electronic Submissions for Medical Device PMAs
The U.S. Food and Drug Administration (FDA) is taking another significant step toward modernizing the way medical device companies prepare and submit Premarket Approval Applications (PMAs). In September 2026, FDA issued a draft guidance on the Electronic Submission Template for Premarket Approval Applications (PMA). The guidance introduces the current electronic resources available for PMA and […]
29 Sep
AI Enters Cosmetic Safety and Adverse-Event Monitoring
AI Enters Cosmetic Safety and Adverse-Event Monitoring: From Reactive Reporting to Predictive Cosmetovigilance The cosmetics industry is entering a new phase of safety management. As product portfolios become more complex, consumer expectations rise, and regulatory oversight expands, cosmetic companies are facing a growing need to identify, classify, investigate, and respond to adverse events more efficiently. […]